Skip to main content
Premium Trial:

Request an Annual Quote

Agustin de la Calle, D. Lansing Taylor

Premium
VistaGen Therapeutics has named Agustin de la Calle vice president of business development, the company announced this week.
 
De la Calle was previously head of business development at Innate Pharma, director of business development at Micromet, and manager of business development at Exelixis. He has also served as a senior analyst with the Mendel Group and as a protein scientist at EOS Biotechnology.  
 

 
The board of directors of the Pittsburgh Life Sciences Greenhouse this week announced that it has approved the nomination of D. Lansing Taylor as the new chairman of the board of the PLSG.
 
Taylor is the president and CEO of Cellumen. Prior to Cellumen, he was the founder, chairman, and CEO of Cellomics, which was acquired by ThermoFisher Scientific. Taylor had previously been a co-founder, board member, and a scientific advisor to Biological Detection Systems, until it was sold to Amersham Biosciences in 1996.
 
Taylor was a professor of biological sciences, vice dean of molecular sciences, and director of the National Science Foundation Science and Technology Center at Carnegie Mellon between 1982 and 1996. He continues as an adjunct professor at Carnegie Mellon.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.